The Next Stage of MDx for Women's Health:

Exploring the Significance of Analyzing Individual HPV Types and Simultaneous HPV & STI Testing

<aside> ⏰ Thursday, November 09 at 10:00 am (CET)

</aside>

🔻 Click here to registration

Microsoft Virtual Events Powered by Teams

🔻 Click here to join the webinar

🔻 Click here for a survey (after the webinar)

Microsoft Forms

Join our webinar to gain insights and engage in a discussion on the importance of analyzing individual HPV types and conducting simultaneous HPV & STI testing for women's health.

This webinar will cover the impact of cervicovaginal microbiome that potentially increases the risk of cervical abnormalities, and will share HPV prevalence in Lazio(Italy) with HPV genotype analysis cases using SG STATS.

It will also be an opportunity to discuss and explore the next steps in MDx for Women's Health by sharing insights from our speakers.

📢 Speaker 1:

Dr. Anja Oštrbenk

Analyst in Laboratory Biomedicine Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana

Slovenia

📄 Lecture Title:

Clinical validation of Allplex HPV HR Detection Test for cervical cancer screening

Here’s what you can

• Learn about the international guidelines and protocols for HPV test products.
• Share Slovenia’s cervical cancer screening status and guideline, and the clinical validation results of the Allplex HPV HR Detection.
• Discover the insights of the importance of considered factors for cervical cancer screening.